Vimarsana
Biggest News Aggregation in the World

Page 18 - End Results Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from End Results Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In End Results Program Today - Breaking & Trending Today

Increased Suicide Risk Seen for Patients Undergoing Cancer Surgery - Vimarsana News

Increased Suicide Risk Seen for Patients Undergoing Cancer Surgery

FRIDAY, Jan. 13, 2023 (HealthDay News) -- The incidence of suicide is increased among patients undergoing cancer surgery, according to a study published online Jan. 12 in JAMA Oncology. Alexandra L. Potter, from Massachusetts General Hospital in Boston, and colleagues conducted a retrospective cohort study using data from the Surveillance, Epidemiology, and End Results Program

Mainz Biomed Provides Year-End 2022 Corporate Review - Vimarsana News

Mainz Biomed Provides Year-End 2022 Corporate Review

Mainz Biomed Provides Year-End 2022 Corporate Review - read this article along with other careers information, tips and advice on BioSpace

BeiGene's BRUKINSA (zanubrutinib) Demonstrated Superior Progression-Free Survival Over IMBRUVICA (ibrutinib) in Chronic Lymphocytic Leukemia in Late-Breaker at ASH - Vimarsana News

BeiGene's BRUKINSA (zanubrutinib) Demonstrated Superior Progression-Free Survival Over IMBRUVICA (ibrutinib) in Chronic Lymphocytic Leukemia in Late-Breaker at ASH

Final ALPINE Progression-Free Survival (PFS) results simultaneously published in The New England Journal of Medicine and presented at late-breaking session at 64th American Society of Hematology Annual

Capivasertib plus FASLODEX® (fulvestrant) reduced the risk of disease progression or death by 40% versus FASLODEX in advanced HR-positive breast cance - Vimarsana News

Capivasertib plus FASLODEX® (fulvestrant) reduced the risk of disease progression or death by 40% versus FASLODEX in advanced HR-positive breast cance

Capivasertib plus FASLODEX® (fulvestrant) reduced the risk of disease progression or death by 40% versus FASLODEX in advanced HR-positive breast cancer CAPItello-291 Phase III trial results presented at SABCS 2022 show potential of capivasertib as first-in-class AKT inhibitor  WILMINGTON, Del., Decembe...

Investegate |AstraZeneca PLC Announcements | AstraZeneca PLC: Capivasertib PFS in HR-positive breast cancer - Vimarsana News

Investegate |AstraZeneca PLC Announcements | AstraZeneca PLC: Capivasertib PFS in HR-positive breast cancer

Investegate announcements from AstraZeneca PLC, Capivasertib PFS in HR-positive breast cancer